Ambrx Biopharma Inc
AMAM
AMAM was delisted on the 6th of March, 2024.
20 hedge funds and large institutions have $266M invested in Ambrx Biopharma Inc in 2021 Q2 according to their latest regulatory filings, with 20 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
39.85% more ownership
Funds ownership: 0% → 39.85% (+40%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$64.2M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$42.4M |
| 3 |
FI
Fosun International
Hong Kong,
China
|
+$32.9M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$31.1M |
| 5 |
SCM
Suvretta Capital Management
New York
|
+$19.9M |
Top Sellers
AMAM Hedge Fund Activity: Q2 2021 in Review
20 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Ambrx Biopharma Inc (AMAM) for Q2 2021, worth a combined $266M.
Buyers outnumbered sellers: 20 funds opened new AMAM positions and 0 closed out — a net gain of 20 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $64.2M.
- 20 institutional investors held Ambrx Biopharma Inc (AMAM) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $266M of Ambrx Biopharma Inc stock for Q2 2021.
- 20 funds opened new Ambrx Biopharma Inc positions in Q2 2021 and 0 closed out, a net change of +20 holders.
- The largest Ambrx Biopharma Inc buyer in Q2 2021 was Fidelity Investments, an estimated $64.2M added.
Based on aggregated 13F filings for Q2 2021.